US sen­a­tors ac­cuse No­var­tis ex­ecs of greed for hid­ing ma­nip­u­lat­ed Zol­gens­ma da­ta — and the next step could af­fect the in­dus­try

The sec­ond act in No­var­tis’ Zol­gens­ma dra­ma opened on Fri­day.

A group of US sen­a­tors is­sued their own fu­ri­ous slap­down for the com­pa­ny’s de­ci­sion to keep in­for­ma­tion about ma­nip­u­lat­ed da­ta on Zol­gens­ma hid­den from the FDA dur­ing the re­view process. And this at­tack in­cludes a shot right over the in­dus­try’s bow — with po­ten­tial con­se­quences for all drug de­vel­op­ers.

The let­ter — signed by a group that in­cludes two De­mo­c­ra­t­ic can­di­dates for pres­i­dent, Bernie Sanders and Eliz­a­beth War­ren — ac­cused No­var­tis of greed as well as an out­ra­geous re­fusal to ex­press re­morse in its state­ment re­gard­ing the in­ci­dent in­volv­ing Zol­gens­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER